Efficacy And Safety Of Salvianolic Acids In Treatment Of Acute Cerebral Infarction Complicated With Silent Myocardial Ischemia

Background:Study on the efficacy and safety of salvianolic acid in the treatment of acute cerebral infarction with silent myocardial ischemia.With the change of people’s life style and the aging of the population,the incidence of cerebral infraction in China is getting higher and higher.Compared with the patients with simple cerebral infraction,the recovery of neurological deficits and activities of daily living were worse than those complicated with silent myocardial ischemia.In addition to the treatment of cerebral infraction,the present study for salvianolic acid was mainly focused on the pharmacological mechanism and clinical efficacy of cerebral infarction,while,there are less research on the clinical efficacy and safety of acute cerebral infarction patients with silent myocardial ischemia.Objective:To study the effect of salvianolic acid on the recovery of neurological deficits,activity of daily living and ST segment depression amplitude and the clinical safety in patients with acute cerebral infarction complicated with silent myocardial ischemia.Methods:The study was conducted in the Eastern Division of the First Hospital of Jilin University from March 2015 to October 2016,300 patients with acute cerebral infarction were enrolled.Among them,there were 200 patients with silent myocardial ischemia,and none of them with silent myocardial ischemia in 100 cases.The patients with cerebral infarction were randomly divided into 2 groups,one of them is medication group with myocardial chemia,the other one is the control group with myocardial chemia.Futhermore,the 100 pattients without myocardial ischemia with the treatment of salvianolic acid named non myocardial ischemia medication group.Before treatment,300 patients received general data collection,NIHSS score,ADL score,24 h dynamic electrocardiogram and the maximum ST segment depression amplitude.After 2 weeks of treatment,all patients were performed with NIHSS score,24 h dynamic electro-cardiogram and summary of adverse reactions during treatment.Telephone follow-up was performed at 3 months after treatment to assess NIHSS score and ADL score.Results:1.Comparing the medication group with myocardial chemia to the control group with myocardial chemia,there was significant difference in the curative effect after 2 weeks(P<0.05);the NIHSS score after 2 weeks,the NIHSS score and ADL score after 3 months were statistically significant(P<0.05).2.After two weeks of treatment,The differences of ST segment depression amplitude between medication group with myocardial chemia and control group with myocardial chemia were significant(P<0.05).3.Comparing the medication group with myocardial chemia to non myocardial ischemia medication group,there was no significant difference in the curative effect after 2 weeks(P>0.05);the NIHSS score after 2weeks,the NIHSS score and ADL score after 3 months were no statistical difference(P>0.05).4.The side effects of the three groups were less,and there were no statistically difference between them.Conclusions:1.Salvianolic acid can significantly improve the neurological deficits and activities of daily living in patients with acute cerebral infarction combined with symptomatic myocardial ischemia,and reduce the adverse prognosis.2.Salvianolic acid can reduce the amplitude of ST segment depression and improve the degree of myocardial ischemia in patients with acute cerebral infarction combined with symptomatic myocardial ischemia.3.Salvia miltiorrhiza injection is a safe and effective therapeutic tool for the treatment of cerebral infarction combined with myocardial ischemia,which is worthy of clinical promotion.